Promising combo for resistant colon cancer never gets off the ground
NCT ID NCT06603818
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II study aimed to test two immunotherapy drugs (tiragolumab and atezolizumab) combined with targeted radiation in people with microsatellite stable (MSS) metastatic colorectal cancer, a type that typically doesn't respond to immunotherapy. The trial was withdrawn before enrolling any participants, so no data were collected. The goal was to find a safe dose and see if the combination could slow cancer growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tiragolumab and atezolizumab (immunotherapy drugs) plus stereotactic body radiation therapy
- What this could lead to
- If it worked, this combination could offer a new treatment option for people with a hard-to-treat form of colorectal cancer that doesn't respond to standard immunotherapy.
- What could go wrong
- The trial was withdrawn before enrolling any participants, so no results are available. Immunotherapies can cause immune-related side effects, and it's unknown if this combination would be effective in MSS colorectal cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?